What is the status of clinical trials of erdafitinib? Analysis of the latest research progress

Erdafitinib is an oral targeted drug mainly used to treat advanced or metastatic urothelial cancer (UC) with FGFR mutations. The drug's mechanism of action is to prevent the growth and proliferation of tumor cells by inhibiting the FGFR (fibroblast growth factor receptor) signaling pathway. According to data from multiple clinical trials, erdafitinib has shown significant efficacy in the treatment of cancers related to FGFR mutations, especially in the treatment of urothelial cancer.

Erdafitinib has been proven to have good therapeutic effects in multiple clinical trials. For example, in the THOR trial, erdafitinib demonstrated significant clinical benefit in patients with advanced urothelial cancer who had already received chemotherapy. Data from this study show that the objective response rate (ORR) of erdafitinib is around 40%, and the disease control period (DCR) of some patients is also significantly prolonged. The results make erdafitinib an effective treatment option in certain patients with FGFR mutations.

Although erdafitinib has shown good efficacy in multiple clinical studies, it also faces certain drug resistance problems. During long-term treatment, some patients may develop drug resistance. In order to deal with this problem, researchers are exploring combination drug strategies, such as combination with other targeted drugs or immune checkpoint inhibitors, in order to improve efficacy and delay the occurrence of drug resistance. In addition, erdafitinib also shows certain side effects. The most common side effects include rash, oral ulcers, eye discomfort, etc. These side effects can usually be alleviated with dose adjustment and symptomatic treatment.

As more clinical trials are conducted, the indications and application scope of erdafitinib are gradually expanding. In recent years, some studies have used it to treat other types of tumors, such as certain types of head and neck cancer, liver cancer, etc. These studies are further validating the effect of erdafitinib in different tumor types. At the same time, clinical researchers are also exploring how to maximize its clinical benefits, such as selecting the most suitable patient groups through precision medicine methods to further improve the level of individualization of treatment.

Reference link:https://www.balversa.com/